
Publication
United States Corporate Transparency Act off again
The US Corporate Transparency Act (CTA) is a law that requires companies to disclose information on their beneficial owners.
United States | Publication | February 14, 2022
The US Securities and Exchange Commission (SEC) took another step closer this week towards its aim to provide greater oversight of private funds. On February 9, 2022, the SEC approved and passed, by a three to one vote, a proposal requiring private equity and hedge funds to provide basic disclosures to their investors and guard against conflicts. This proposal comes less than a month after the SEC announced proposed disclosure rules aimed at obtaining more information from private equity and hedge funds to help regulators better spot risks in private markets, which we discussed in this previous legal update.
If approved, these proposed disclosures would not have to be filed with the SEC or made public. Instead, private funds would generally be required to maintain books and records to allow regulators to assess their compliance with the rules. Additionally, the proposal identifies and prohibits a myriad of activities related to private funds with the aim of addressing what the SEC perceives as a "lack of governance mechanisms" by private fund advisers. Under the proposal:
The proposed amendments will be open for comment for 60 days following publication of the proposing release on the SEC’s website or 30 days following publication of the proposing release in the Federal Register, whichever period is later.
Special thanks to Emma Yeremou-Ngah for her assistance in the preparation of this content.
Publication
The US Corporate Transparency Act (CTA) is a law that requires companies to disclose information on their beneficial owners.
Publication
Health Canada has published a Notice of Intent to publish a ministerial order to exempt natural health products (NHPs) licensed between June 21, 2025, and June 21, 2028, from labelling requirements that are set to come into force this summer under the Natural Health Products Regulations (NHPR).
Subscribe and stay up to date with the latest legal news, information and events . . .
© Norton Rose Fulbright LLP 2025